<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759042</url>
  </required_header>
  <id_info>
    <org_study_id>PRO140 CD02_EA</org_study_id>
    <nct_id>NCT02759042</nct_id>
  </id_info>
  <brief_title>An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study</brief_title>
  <acronym>CD02_EA</acronym>
  <official_title>An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CytoDyn, Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective is to provide continued access to PRO 140 to a subject who has
      completed participation in PRO140_CD02.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single center study designed to provide continued access to PRO 140 to
      a subject who have completed participation in PRO140_CD02 and continue to receive clinical
      benefit.

      The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the
      Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a
      qualified medical professional or self-administered by the subject.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>HIV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO 140</intervention_name>
    <description>PRO 140 is a humanized IgG4,Îº monoclonal antibody (mAb) to the chemokine receptor CCR5.</description>
    <other_name>PRO140</other_name>
    <other_name>CCR5 antagonist</other_name>
    <other_name>Humanized monoclonal antibody to CCR5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        This study will recruit one treatment-experienced, HIV-1 infected patient with CCR5-tropic
        virus, who has participated in PRO 140_CD02 clinical trial and is continuing to derive
        clinical benefit from PRO 140 treatment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>56 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Edwin DeJesus, MD, FIDSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Immunology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CD02 EA Investigational site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>HIV Antibodies</mesh_term>
    <mesh_term>PRO-140 monoclonal antibody</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

